Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs industry growth. The global opioid induced constipation drugs industry was valued at USD 1,933.2 Mn in 2014 and is expected to reach USD 2,779.2 Mn by 2022 with the industry growing at a CAGR of 4.6% during 2016-2022.
North America is the dominant regional OIC drugs industry through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs industry in North America. On the other hand, Germany, UK, and Spain are the major countries setting the industry dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US